Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.61 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4930096 | 1.00 | S1PR1 (0.61) | S1PR1S1PR3TP53MAPTLMNA | |
| SCHEMBL4931695 | 0.93 | S1PR1 (0.60) | S1PR1S1PR3TP53MAPTLMNA | |
| SCHEMBL4619069 | 0.93 | S1PR1 (0.59) | S1PR1S1PR3TP53MAPTLMNA | |
| SCHEMBL4923479 | 0.90 | S1PR1 (0.56) | S1PR1S1PR3TP53MAPTLMNA | |
| SCHEMBL4618456 | 0.87 | S1PR1 (0.48) | S1PR1TP53MAPTLMNAHAVCR2 | |
| SCHEMBL4934613 | 0.85 | S1PR1 (0.52) | S1PR1S1PR3MAPTHAVCR2S1PR5 | |
| SCHEMBL4618961 | 0.85 | MEN1 (0.64) | S1PR1S1PR3TP53MAPTLMNA | |
| SCHEMBL4618965 | 0.85 | MEN1 (0.64) | S1PR1S1PR3TP53MAPTLMNA | |
| SCHEMBL3275081 | 0.85 | S1PR1 (0.47) | S1PR1S1PR3MAPT | |
| SCHEMBL4929190 | 0.85 | S1PR1 (0.45) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | SOX18, SIGMAR1, SUCNR1 | S1PR1 13/4885S1PR3 22/4885TP53 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.